Combined company will operate under the name “TuHURA Biosciences, Inc.” and advance a personalized cancer vaccine platform and preclinical tumor...
SAN DIEGO, May 23, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing...
CTS Activities will Focus on Analytic Method Transfer, Manufacturing of R&D Engineering Batches, and Stability Studies to Support Planned Clinical...
Planegg/Martinsried, May 22, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and...
– Funds will support advancement of two KRAS inhibitor programs into the clinic in 2024 –– Financing led by Avidity...
Five presentations showcase the modularity and applicability of Senti’s Gene Circuit technology in NK cells, T cells, AAVs, iPSCs, and...
12 of 16 voting-eligible advisors vote “no” (with two abstentions) on question, “given the available efficacy and safety data, do...
Early-stage data presented at the 26th Annual Meeting of the American Society for Gene and Cell Therapy demonstrate that therapy...
Rehovot, Israel, May 19, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company”), a telehealth, medical...
BRISBANE, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics...
Also installs high-tech MRI scanner to serve broader set of patients Mount Sinai Brooklyn Infusion Center/Breast Center Opening Event Dr....
Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec) for the Treatment of Dystrophic Epidermolysis...
Treatment with CAN-3110 in arm A showed encouraging median overall survival rate at 11.8 months after a single injection. These...
KT-253 is a novel, highly potent and selective heterobifunctional degrader of the MDM2 oncoprotein with a differentiated profile from small...
RNA Gene Writing™ platform demonstrates continued advances in rewriting to correct pathogenic mutations responsible for phenylketonuria (PKU), alpha-1 antitrypsin deficiency...
Revenue for the first three months of 2023 increased to $15.9 million, compared to $0.8 million for the same...
Revenue for the first three months of 2023 increased to $15.9 million, compared to $0.8 million for the same period...
NEW YORK, May 18, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical...
VANCOUVER, British Columbia, May 18, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional...
FAP-CAR-IL-15 iNKT cell therapy (MiNK-215) promotes curative responses driving tumor elimination and immune infiltration in NSCLC modelsIND enabling studies underway;...